Alogliptin: A dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetesSeptember 1st 2008
Alogliptin is a highly selective DPP-IV inhibitor under investigation for the treatment of type 2 diabetes. An NDA for alogliptin was submitted in January 2008, and a response from FDA is expected in the fourth quarter of this year.
Addition of aliskiren to losartan provides additional renal protective effects in hypertensive patients with type 2 diabetic nephropathyAugust 1st 2008
A recent multinational, randomized, double-blind, placebo-controlled clinical trial demonstrated that administration of aliskiren provides additional renal protection to patients with hypertension, type 2 diabetes mellitus, and nephropathy who are already receiving optimal antihypertensive therapy and renal protective therapy with the angiotensin receptor blocker (ARB) losartan.
ADVANCE: Perindopril plus indapamide reduces vascular events in patients with type 2 diabetesOctober 1st 2007
In a multicenter, multinational, randomized controlled study, a fixed-dose combination of perindopril/ indapamide was associated with a reduced risk of death and vascular events in patients with type 2 diabetes, many of whom were already taking antihypertensive drugs.
Older agents for type 2 diabetes equal or superior to newer agents for glycemic control, lipid levels, body weightOctober 1st 2007
An extensive systematic review published in the Annals of Internal Medicine demonstrated that older oral drugs for type 2 diabetes are just as, if not more, effective than newer agents for gylcemic control, lipid control, and other intermediate end points.
From the 67th annual scientific sessions of the American Diabetes Association: Nebivolol demonstrates neutral effect on glucose levelsAugust 1st 2007
Nebivolol, an investigational (NDA submitted) vasodilating beta-blocker, demonstrated a neutral effect on blood glucose levels in two 12-week clinical studies of patients with hypertension.
From the 67th annual scientific sessions of the American Diabetes Association: Pulmonary effects of inhaled insulin are small, reversibleAugust 1st 2007
Investigators have demonstrated that patients with type 2 diabetes who use inhaled insulin as part of their basalbolus insulin regimen experience a small decline in pulmonary function.
From the 67th annual scientific sessions of the American Diabetes Association: Exenatide associated with sustained blood glucose control, weight loss after 3 years of treatmentAugust 1st 2007
An open-label extension study of exenatide demonstrated sustained blood glucose control and weight loss in patients with type 2 diabetes.
From the 67th annual scientific sessions of the American Diabetes Association: Quick-release bromocriptine has favorable cardiovascular safety profileAugust 1st 2007
A quick-release formulation of bromocriptine reduces the incidence of diabetic cardiovascular complications in patients with type 2 diabetes and improves glycemic control in those patients who did not achieve HbA1c <7.5% with metformin plus a sulfonylurea.
From the 67th annual scientific sessions of the American Diabetes Association: Lipid-lowering therapies reduce development of peripheral neuropathyAugust 1st 2007
Statins and fibrates reduce the risk of peripheral neuropathy in patients with type 2 diabetes independent of the agents' effects on lipids, according to results presented at the 67th annual scientific sessions of the American Diabetes Association.
From the 67th annual scientific sessions of the American Diabetes Association: PROactive: Pioglitazone improves CV outcomes in patients with renal dysfunction, type 2 diabetes, and macrovascular diseaseAugust 1st 2007
The use of pioglitazone in patients with renal dysfunction, type 2 diabetes, and macrovascular disease can reduce the risk of death, nonfatal myocardial infarction (MI), and stroke according to results presented at the 67th annual scientific sessions of the American Diabetes Association.
From the 67th annual scientific sessions of the American Diabetes Association: Researchers debate the CV safety of rosiglitazoneAugust 1st 2007
Rosiglitazone did not demonstrate an increased risk of hospitalizations and death from cardiovascular causes (the composite end point) in an interim analysis of a prospective study.
Diabetes associations develop consensus algorithm for the management of hyperglycemia in type 2 diabetesNovember 1st 2006
The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) have developed a consensus algorithm for the management of hyperglycemia in type 2 diabetes. The statement, published in the August issue of Diabetes Care, was created for several reasons.
DREAM trial: Rosiglitazone reduces the incidence of new-onset diabetesNovember 1st 2006
In a randomized, double-blind, placebo-controlled trial recently published in Lancet, the thiazolidinedione (or "glitazone") rosiglitazone statistically significantly reduced the incidence of new-onset diabetes when given to patients diagnosed with prediabetes but lacking a prior history of cardiovascular disease. The benefits of using thiazolidinediones in the treatment of patients with diabetes are well known, but the current finding that thiazolidinediones can prevent prediabetics from progressing to diabetes is novel.
DREAM trial: Ramipril fails to reduce the incidence of new-onset diabetes or deathNovember 1st 2006
In a randomized, double-blind, placebo-controlled trial, the angiotensin-converting enzyme (ACE) inhibitor ramipril, when administered to patients with prediabetes but no previous cardiovascular disease, failed to demonstrate a statistically significant reduction in the primary composite end point of new-onset diabetes or death.
Rimonabant: A novel CB1 receptor antagonist for the treatment of obesityNovember 1st 2006
Obesity is on the rise in the United States, with 60.5% of the adult population overweight and 23.9% obese as of 2005. Up to 10% of an industrialized country's healthcare budget often can be spent on obesity and associated comorbidities.
Effect of a medication assistance program on clinical outcomes in patients with diabetesOctober 1st 2006
Approximately 17 million people in the United States have type 2 diabetes, and the prevalence continues to rise.1 More than 45% of patients with end-stage renal disease have type 2 diabetes as an etiology, and a patient with type 2 diabetes has the same risk of developing an acute coronary syndrome (unstable angina, myocardial infarction [MI]) over the next 10 years as someone who has had an acute coronary syndrome in the past.2 In addition to these complications, type 2 diabetes also increases the risk of blindness, neuropathy, and amputation.3
Vildagliptin: A dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetesOctober 1st 2006
Despite the variety of medications available to treat type 2 diabetes, the disease is inadequately controlled in many patients. In order to improve glycemic control, manufacturers are pursuing compounds that affect the incretin hormones that stimulate insulin release in response to increased glucose levels. Although stimulation of the incretin receptors by the glucagon-like peptide-1 (GLP-1) enhances the body's ability to produce insulin in response to elevated blood glucose concentrations, the clinical usefulness of GLP-1 is limited by its rapid degradation by dipeptidyl peptidase-IV (DPP-IV). Drug companies have developed compounds intended to act as inhibitors of DPP-IV. Vildagliptin (Galvus, Novartis) is the second DPP-IV inhibitor under investigation by FDA to offer this new mechanism to achieve glycemic control. An NDA for vildagliptin was submitted to FDA in March 2006, 1 month after the submission of the first DPP-IV inhibitor, sitagliptin.
New data emerge on the relationship between diabetic, pre-diabetic conditions and Alzheimer's diseaseSeptember 1st 2006
Three studies presented at the 10th International Conference on Alzheimer's Disease and Related Disorders in Madrid, Spain, yielded new data regarding the relationship between diabetic and pre-diabetic conditions and the subsequent development and treatment of Alzheimer's disease (AD).
Elevated atorvastatin dosage reduces rate of cardiovascular events in CHD patientsSeptember 1st 2006
Intensive therapy with atorvastatin 80 mg/d, in comparison with the same medication at 10 mg/d, significantly reduced the rate of major cardiovascular events by 25% in patients with clinically evident stable coronary heart disease (CHD) and diabetes, according to a study published in Diabetes Care.
Atorvastatin fails to demonstrate significant benefit in treatment of CV disease in patients with diabetesSeptember 1st 2006
Atorvastatin showed no statistically significant difference in the reduction of a composite cardiovascular disease (CVD) end point in type 2 diabetes patients, according to a randomized, double-blind, parallel-group study.